These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26269114)

  • 41. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.
    Pallis AG; Syrigos KN
    Lung Cancer; 2013 May; 80(2):120-30. PubMed ID: 23384674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women.
    Chen KY; Hsiao CF; Chang GC; Tsai YH; Su WC; Chen YM; Huang MS; Hsiung CA; Chen CJ; Yang PC;
    Carcinogenesis; 2013 Mar; 34(3):612-9. PubMed ID: 23239743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients.
    Shitara M; Sasaki H; Yokota K; Okuda K; Hikosaka Y; Moriyama S; Yano M; Kawaguchi T; Kubo A; Takada M; Kitahara N; Okumura M; Matsumura A; Iuchi K; Fujii Y
    Exp Ther Med; 2012 Nov; 4(5):785-789. PubMed ID: 23226726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.
    Jung M; Cho BC; Lee CH; Park HS; Kang YA; Kim SK; Chang J; Kim DJ; Rha SY; Kim JH; Lee JH
    Yonsei Med J; 2012 Nov; 53(6):1128-35. PubMed ID: 23074112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population.
    Hou WG; Ai WB; Bai XG; Dong HL; Li Z; Zhang YQ; Xiong LZ
    PLoS One; 2012; 7(5):e37531. PubMed ID: 22662167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
    Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
    PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
    Liu G; Cheng D; Ding K; Le Maitre A; Liu N; Patel D; Chen Z; Seymour L; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Feb; 7(2):316-22. PubMed ID: 22237259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. AKT1 polymorphisms and survival of early stage non-small cell lung cancer.
    Kim MJ; Kang HG; Lee SY; Jeon HS; Lee WK; Park JY; Lee EB; Lee JH; Cha SI; Kim DS; Kim CH; Kam S; Jung TH; Park JY
    J Surg Oncol; 2012 Feb; 105(2):167-74. PubMed ID: 21842521
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
    Ferlay J; Shin HR; Bray F; Forman D; Mathers C; Parkin DM
    Int J Cancer; 2010 Dec; 127(12):2893-917. PubMed ID: 21351269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Global cancer statistics.
    Jemal A; Bray F; Center MM; Ferlay J; Ward E; Forman D
    CA Cancer J Clin; 2011; 61(2):69-90. PubMed ID: 21296855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions.
    Liu W; He L; Ramírez J; Krishnaswamy S; Kanteti R; Wang YC; Salgia R; Ratain MJ
    Cancer Res; 2011 Apr; 71(7):2423-7. PubMed ID: 21292812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.
    Su Z; Dias-Santagata D; Duke M; Hutchinson K; Lin YL; Borger DR; Chung CH; Massion PP; Vnencak-Jones CL; Iafrate AJ; Pao W
    J Mol Diagn; 2011 Jan; 13(1):74-84. PubMed ID: 21227397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer.
    Giovannetti E; Erdem L; Olcay E; Leon LG; Peters GJ
    Front Biosci (Landmark Ed); 2011 Jan; 16(1):116-30. PubMed ID: 21196162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M; Inoue A; Kobayashi K; Sugawara S; Oizumi S; Isobe H; Gemma A; Harada M; Yoshizawa H; Kinoshita I; Fujita Y; Okinaga S; Hirano H; Yoshimori K; Harada T; Ogura T; Ando M; Miyazawa H; Tanaka T; Saijo Y; Hagiwara K; Morita S; Nukiwa T;
    N Engl J Med; 2010 Jun; 362(25):2380-8. PubMed ID: 20573926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.